Novel therapeutics in ovarian cancer: Expanding the toolbox Review

   


Authors: Moufarrij, S.; O'Cearbhaill, R. E.
Review Title: Novel therapeutics in ovarian cancer: Expanding the toolbox
Abstract: Despite high response rates to initial therapy, most patients with ovarian cancer will ultimately recur and go on to develop resistance to standard treatments. Novel therapies have been developed to overcome drug resistance and alter the tumor immune microenvironment by targeting oncogenic pathways, activating the innate immune response, and enhancing drug delivery. In this review, we discuss the current and future roles of chemotherapy, targeted agents such as poly (ADP-ribose) polymerase (PARP) inhibitors, bevacizumab, and mirvetuximab in the treatment of ovarian cancer. We explore the emerging role of therapeutic targets, including DNA repair pathway inhibitors and novel antibody-drug conjugates. Furthermore, we delve into the role of immunotherapeutic agents such as interleukins as well as immune-promoting agents such as oncolytic viruses and cancer vaccines. Innovative combination therapies using these agents have led to a rapidly evolving treatment landscape and promising results for patients with recurrent ovarian cancer.
Keywords: bevacizumab; ovarian cancer; ovarian neoplasms; neoplasm recurrence, local; monoclonal antibody; tumor recurrence; ovary tumor; ovary carcinoma; oncolytic viruses; nanoparticle; vaccines; resistance; tumor microenvironment; experimental therapy; therapies, investigational; humans; human; female; homologous recombination deficiency; checkpoint inhibition; carcinoma, ovarian epithelial; antibody–drug conjugate; poly (adp-ribose) polymerase inhibition
Journal Title: Current Oncology
Volume: 31
Issue: 1
ISSN: 1198-0052
Publisher: Multimed Inc  
Date Published: 2023-01-01
Start Page: 97
End Page: 114
Language: English
DOI: 10.3390/curroncol31010007
PUBMED: 38248092
PROVIDER: scopus
PMCID: PMC10814452
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183081766&doi=10.3390%2fcurroncol31010007&partnerID=40&md5=4b6f4af7dcb38595df15e1596c2b6053
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author is Roisin E. O’Cearbhaill -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Roisin Eilish O'Cearbhaill
    272 O'Cearbhaill
  2. Sara Maria Moufarrij
    20 Moufarrij
Related MSK Work